Kyverna Therapeutics, Inc.
KYTX
$1.87
-$0.04-2.09%
| Weiss Ratings | KYTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | KYTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | KYTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | KYTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -6.50% | |||
| 30-Day Total Return | -35.52% | |||
| 60-Day Total Return | -45.80% | |||
| 90-Day Total Return | -63.41% | |||
| Year to Date Total Return | -52.30% | |||
| 1-Year Total Return | -91.97% | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -92.33% | |||
| 52-Week Low % Change | 6.70% | |||
| Price | KYTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $24.91 | |||
| 52-Week Low Price | $1.79 | |||
| 52-Week Low Price (Date) | Apr 07, 2025 | |||
| 52-Week High Price (Date) | Apr 10, 2024 | |||
| Valuation | KYTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 82.54M | |||
| Enterprise Value | -195.20M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.46 | |||
| Earnings Per Share Growth | -95.63% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.31 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $1.87 | |||
| Enterprise Value/EBITDA (TTM) | 1.38 | |||
| Enterprise Value/EBIT | 1.37 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | KYTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 43.23M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | KYTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | (510) 925-2492 | |||
| Address | 5980 Horton Street Emeryville, CA 94608 | |||
| Website | kyvernatx.com | |||
| Country | United States | |||
| Year Founded | 2018 | |||
| Profitability | KYTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | KYTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -46.93% | |||
| Return on Equity | -- | |||
| Income Statement | KYTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -112.47M | |||
| EBITDA (TTM) | -141.42M | |||
| EBIT (TTM) | -142.60M | |||
| Net Income (TTM) | -127.48M | |||
| Net Income Avl. to Common (TTM) | -127.48M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -81.40% | |||
| EPS Diluted (TTM) | -3.46 | |||
| EPS Diluted Growth (Q YOY) | 96.66% | |||
| Balance Sheet | KYTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 285.98M | |||
| Cash Per Share (Q) | $6.62 | |||
| Total Current Assets (Q) | 290.60M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 266.59M | |||
| Current Ratio (Q) | 8.609 | |||
| Book Value Per Share (Q) | $6.17 | |||
| Total Assets (Q) | 304.65M | |||
| Total Current Liabilities (Q) | 33.76M | |||
| Total Debt (Q) | 8.24M | |||
| Total Liabilities (Q) | 38.06M | |||
| Total Common Equity (Q) | 266.59M | |||
| Cash Flow | KYTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -160.90M | |||
| Cash from Financing (TTM) | 337.11M | |||
| Net Change in Cash (TTM) | 61.96M | |||
| Levered Free Cash Flow (TTM) | -69.56M | |||
| Cash from Operations (TTM) | -114.25M | |||
